Serarslan Alparslan, Gursel Bilge, Okumus Nilgun Ozbek, Meydan Deniz, Sullu Yurdanur, Gonullu Guzin
Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayis University , Samsun, Turkey E-mail :
Asian Pac J Cancer Prev. 2015;16(15):6673-9. doi: 10.7314/apjcp.2015.16.15.6673.
Male breast cancer is a rare neoplasm, and its treatments are based on those of female breast cancer. This study aimed to analyze 20 years of male breast cancer clinical characteristics and treatment results from the Middle Black Sea Region of Turkey.
A retrospective analysis of 16 male breast cancer patients treated in our tertiary hospital between 1994 and 2014 was performed. Epidemiologic data, tumor characteristics, and treatments were recorded and compared with 466 female breast cancer ((premenopausal; n=230)+(postmenopausal n=236)) patients. The 5-year disease-free and overall survival rates were calculated.
Male breast cancer constituted 0.1% of all malignant neoplasms in both sexes, 0.2% of all malignant neoplasms in males, and 0.7% of all breast cancers. The mean patient age in this study was 59.8±9.5 (39-74) years. The mean time between first symptom and diagnosis was 32.4±5.3 (3-60) months. Histology revealed infiltrative ductal carcinoma in 81.3% of patients. The most common detected molecular subtype was luminal A, in 12 (75%) patients. Estrogen receptor rate (93.8%) in male breast cancer patients was significantly higher than that in female breast cancer (70.8% in all females, p=0.003; 68.2% in postmenopausal females, p=0.002) patients. Most of the tumors (56.3%) were grade 2. Tumor stage was T4 in 50% of males. The majority (56.3%) of the patients were stage III at diagnosis. Surgery, chemotherapy, radiotherapy and endocrine-therapy were applied to 62.5%, 62.5%, 81.2% and 73.3%, respectively. Loco-regional failure did not occur in any of the cases. All recurrences were metastastic. The 5-year disease-free and overall survival rates in male breast cancer patients were 58% and 68%, respectively.
Tumors found in male breast cancer patients were similar in size to tumors found in females, but they advanced to T4 stage more rapidly because of the lack of breast parenchymal tissues. The rate of estrogen receptor expression tended to be higher in male breast cancer patients than in female breast cancer patients. Metastasis is the most important problem in initially non-metastatic male breast cancer patients.
男性乳腺癌是一种罕见肿瘤，其治疗方法基于女性乳腺癌的治疗方法。本研究旨在分析土耳其中黑海地区20年男性乳腺癌的临床特征及治疗结果。
对1994年至2014年在我们三级医院接受治疗的16例男性乳腺癌患者进行回顾性分析。记录流行病学数据、肿瘤特征及治疗情况，并与466例女性乳腺癌患者（绝经前；n = 230）+（绝经后n = 236）进行比较。计算5年无病生存率和总生存率。
男性乳腺癌占所有两性恶性肿瘤的0.1%，占男性所有恶性肿瘤的0.2%，占所有乳腺癌的0.7%。本研究中患者的平均年龄为59.8±9.5（39 - 74）岁。首次症状出现至诊断的平均时间为32.4±5.3（3 - 60）个月。组织学检查显示81.3%的患者为浸润性导管癌。最常见的检测分子亚型为管腔A型，有12例（75%）患者。男性乳腺癌患者的雌激素受体率（93.8%）显著高于女性乳腺癌患者（所有女性为70.8%，p = 0.003；绝经后女性为68.2%，p = 0.002）。大多数肿瘤（56.3%）为2级。50%的男性患者肿瘤分期为T4。大多数（56.3%）患者诊断时为Ⅲ期。分别有62.5%、62.5%、81.2%和73.3%的患者接受了手术、化疗、放疗和内分泌治疗。所有病例均未发生局部区域复发。所有复发均为转移。男性乳腺癌患者的5年无病生存率和总生存率分别为58%和68%。
男性乳腺癌患者中发现的肿瘤大小与女性相似，但由于缺乏乳腺实质组织，肿瘤进展至T4期的速度更快。男性乳腺癌患者雌激素受体表达率往往高于女性乳腺癌患者。转移是初始无转移的男性乳腺癌患者最重要的问题。
